peptide-yy and Hyperplasia

peptide-yy has been researched along with Hyperplasia* in 2 studies

Reviews

1 review(s) available for peptide-yy and Hyperplasia

ArticleYear
The neuroendocrine system of the gut--an update.
    Acta oncologica (Stockholm, Sweden), 1991, Volume: 30, Issue:4

    During the last few years the endocrine stomach has come into focus much due to the side-effects produced by powerful acid blockers. A sustained and marked inhibition of acid secretion in the rat results in hypergastrinemia, with gastrin cell hyperplasia, and a consequent hyperplasia of the ECL cells. This response of the ECL cells was predictable in view of previous observations that sustained hypergastrinemia causes ECL cell hyperplasia. While the gastrin cell hyperplasia levels off at about twice the normal cell density a few weeks after start of treatment, the ECL cells continue to proliferate for months to reach a five-fold higher density than normally. Evidence is accumulating that ECL cells proliferate through self replication. After life-long inhibition of acid production (high doses of ranitidine or omeprazole) or after extirpation of 75% of the acid-producing part of the stomach, ECL cell carcinoids develop. Endocrine cells in the gut often contain more than one putative messenger. Thus, gastrin cells in many species store GABA and peptide YY; in e.g. cat and man they store in addition a xenopsin-like peptide. Neuromedin U and pituitary adenylate cyclase activating peptide (PACAP) have recently been demonstrated in gut nerves. Their role in gut physiology remains to be identified.

    Topics: Animals; Enterochromaffin Cells; gamma-Aminobutyric Acid; Gastric Acid; Gastrins; Humans; Hyperplasia; Neuropeptides; Neurosecretory Systems; Peptide YY; Peptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Stomach

1991

Other Studies

1 other study(ies) available for peptide-yy and Hyperplasia

ArticleYear
H2-receptor blockade induces peptide YY and enteroglucagon-secreting gastric carcinoids in mastomys.
    Surgery, 1989, Volume: 106, Issue:6

    Gastric carcinoid tumor formation has been reported with prolonged achlorhydria in both animals and human beings. The hypothesis in this study was that the ablation of parietal cell function in an animal (mastomys) genetically predisposed to gastric neuroendocrine neoplasia would promote and accelerate tumor formation. Loxtidine, an irreversible H2-receptor blocker, was administered at 1 mg/kg/day in drinking water for 4 months to young mastomys (n = 16). After 4 months of treatment, 14 of 16 animals had gastric carcinoids compared with 0 of 16 young control animals and 4 of 16 older control animals. Ultrastructurally, these tumors were characterized by the presence of neurosecretory granules. Serum gastrin levels were elevated (230 +/- 40 pmol/L) in loxtidine-treated animals compared with control animals (26 +/- 8 pmol/L) (p less than 0.05). In addition, both peptide YY (620 +/- 160 pmol/L) and enteroglucagon (500 +/- 147 pmol/L) were significantly elevated compared with control groups (p less than 0.05). Similarly, in tumor tissue, peptide YY (676 +/- 152 pmol/gm) and enteroglucagon (551 +/- 164 pmol/gm) were found in large quantities, whereas gastrin was undetectable. These observations provide substantial support for the possible pathophysiologic role of gut peptides, particularly gastrin, in the generation of endocrine neoplasia. The advent of endocrine tumors after inhibition of a gut secretory cell (parietal) may be of considerable significance in understanding the genesis of endocrine neoplasia. Whether the drug acts as a neoplastic promoter of enterochromaffin-like cells or the tumor development is related to elevation of peptides such as gastrin cannot be established in this study. Long-term H2-receptor blockade with new potent, irreversible agents as an alternative to surgery may have potential grave implications that require careful consideration.

    Topics: Animals; Carcinogens; Carcinoid Tumor; Gastric Mucosa; Gastrointestinal Hormones; Glucagon-Like Peptides; Histamine H1 Antagonists; Hyperplasia; Muridae; Peptide YY; Peptides; Reference Values; Stomach; Stomach Neoplasms; Triazoles

1989